Suchergebnisse - "Fajgenbaum, David C."

PubPharm (4)

1

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease

enthalten in: Blood advances | 2022

von van Rhee, F. | Rosenthal, A. | Kanhai, K. | +4

2

Optimisation of anti-interleukin-6 therapy : Precision medicine through mathematical modelling

enthalten in: Frontiers in immunology | 2022

von Rossi, J. | Chiang, H. | Lu, Z. | +5

3

Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease : secondary analyses of phase II clinical trial data

enthalten in: British journal of haematology | 2019

von Morra, D. | Pierson, S. | Shilling, D. | +6

4

Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease

enthalten in: Blood | 2017

von Yu, L. | Tu, M. | Cortes, J. | +13

CommentIn: Blood. 2017 Mar 23;129(12 ):1570. - PMID 28336728

1
[1]